
14-alpha demethylase inhibitors - Pipeline Insight, 2024
Description
14-alpha demethylase inhibitors - Pipeline Insight, 2024
DelveInsight’s, “14-Alpha Demethylase Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in 14-Alpha Demethylase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
14-Alpha Demethylase Inhibitors: Overview
Sterol 14alpha-demethylase (CYP51) is the most widely distributed of all members of the cytochrome P450 gene superfamily and the only CYP family found in both prokaryotes and eukaryotes. It is well known as a drug target for microbial pathogenic infections.
Function - The biological role of this protein is also well understood. The demethylated products of the CYP51 reaction are vital intermediates in pathways leading to the formation of cholesterol in humans, ergosterol in fungi, and other types of sterols in plants. These sterols localize to the plasma membrane of cells, where they play an important structural role in the regulation of membrane fluidity and permeability and also influence the activity of enzymes, ion channels, and other cell components that are embedded within.
14-Alpha Demethylase Inhibitors – These are the compounds that specifically inhibit STEROL 14-DEMETHYLASE. A variety of azole-derived antifungal agents act through this mechanism. Azoles are currently the most popular class of antifungals used in both agricultural and medical settings. These compounds bind as the sixth ligand to the heme group in CYP51, thereby altering the structure of the active site and acting as noncompetitive inhibitors. The effectiveness of imidazoles and triazoles (common azole subclasses) as inhibitors of 14α-demethylase have been confirmed through several experiments.
14-Alpha Demethylase Inhibitors Emerging Drugs Chapters
This segment of the 14-Alpha Demethylase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
14-Alpha Demethylase Inhibitors Emerging Drugs
- Oteseconazole: Mycovia Pharmaceuticals
- Isavuconazonium: Basilea Pharmaceutica
Further product details are provided in the report……..
14-Alpha Demethylase Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different 14-Alpha Demethylase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on 14-Alpha Demethylase Inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
14-Alpha Demethylase Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses 14-Alpha Demethylase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging 14-Alpha Demethylase Inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence 14-Alpha Demethylase Inhibitors R&D. The therapies under development are focused on novel approaches for 14-Alpha Demethylase Inhibitors.
- 14-Alpha Demethylase Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing 14-Alpha Demethylase Inhibitors drugs?
- How many 14-Alpha Demethylase Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for 14-Alpha Demethylase Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the 14-Alpha Demethylase Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for 14-Alpha Demethylase Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Mycovia Pharmaceuticals
- Basilea Pharmaceutica
- Hill Dermaceuticals
- Zambon
- Pulmocide
- Angelini Pharmaceuticals
- Biolab Sanus Farmaceutica
- Astellas Pharma
- Basilea Pharmaceutica
- Pulmatrix
- Seren Pharmaceuticals
- Merck & Co
- Laboratoires SMB
- ProFem
- Oteseconazole
- Isavuconazonium
- Miconazole
- ZP 059
- PC-945
- Benzydamine/econazole
- BL-123
- BAL 4815
- PUR 1900
- Fosravuconazole
- Posaconazole
- ITZ DPI
- Prof-001
Table of Contents
60 Pages
- Introduction
- Executive Summary
- 14-Alpha Demethylase Inhibitors: Overview
- Structure
- Mechanism of Action
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- 14-Alpha Demethylase Inhibitors – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- 14-Alpha Demethylase Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- 14-Alpha Demethylase Inhibitors Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Pre-registration)
- Comparative Analysis
- Oteseconazole: Mycovia Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- PC-945: Pulmocide
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- ZP 059: Zambon
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- 14-Alpha Demethylase Inhibitors Key Companies
- 14-Alpha Demethylase Inhibitors Key Products
- 14-Alpha Demethylase Inhibitors- Unmet Needs
- 14-Alpha Demethylase Inhibitors- Market Drivers and Barriers
- 14-Alpha Demethylase Inhibitors- Future Perspectives and Conclusion
- 14-Alpha Demethylase Inhibitors Analyst Views
- 14-Alpha Demethylase Inhibitors Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.